Pegylated liposomal doxorubicin and gemcitabine in patients with advanced hepatocellular carcinoma: results of a phase 2 study (Q82354951)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21058409%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

title

Pegylated liposomal doxorubicin and gemcitabine in patients with advanced hepatocellular carcinoma: results of a phase 2 study (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21058409%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

main subject

hepatocellular carcinoma

1 reference

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21058409%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

Umberto Cillo

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21058409%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

Alessandro Vitale

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21058409%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

author name string

Fable Zustovich

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21058409%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

Fabio Farinati

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21058409%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

Giacomo Zanus

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21058409%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

Martin Donach

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21058409%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

Miriam Farina

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21058409%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

Stefania Zovato

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21058409%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

Davide Pastorelli

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21058409%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

publication date

31 August 2010

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21058409%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21058409%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

volume

117

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21058409%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21058409%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

page(s)

125-133

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21058409%20AND%20SRC:MED&resulttype=core&format=json

Estimating the world cancer burden: Globocan 2000.

15 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25578

7 January 2021

Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25578

7 January 2021

Surgical resection versus transplantation for early hepatocellular carcinoma: clues for the best strategy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25578

7 January 2021

Systematic review: evidence-based management of hepatocellular carcinoma--an updated analysis of randomized controlled trials.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25578

7 January 2021

Phase II study of gemcitabine in patients with advanced hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25578

7 January 2021

Doxorubicin versus no antitumor therapy in inoperable hepatocellular carcinoma. A prospective randomized trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25578

7 January 2021

Systemic therapy for advanced hepatocellular carcinoma: a review.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25578

7 January 2021

Phase I and pharmacokinetic study of a stable, polyethylene-glycolated liposomal doxorubicin in patients with solid tumors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25578

7 January 2021

Sorafenib in advanced hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25578

7 January 2021

Topoisomerase I, IIα and IIβ mRNA expression in peripheral blood mononuclear cells of patients with solid tumor: preliminary results

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25578

7 January 2021

In vitro basis for schedule-dependent interaction between gemcitabine and topoisomerase-targeted drugs in the treatment of colorectal cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25578

7 January 2021

Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25578

7 January 2021

A phase II and pharmacokinetic study of pegylated liposomal doxorubicin in patients with advanced hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25578

7 January 2021

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25578

7 January 2021

Optimal two-stage designs for phase II clinical trials

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25578

7 January 2021

Treatment of hepatocellular carcinoma: a systematic review of randomized controlled trials

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25578

7 January 2021

Pegylated liposomal doxorubicin in treating a case of advanced hepatocellular carcinoma with severe hepatic dysfunction and pharmacokinetic study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25578

7 January 2021

Activity and safety of pegylated liposomal doxorubicin, 5-fluorouracil and folinic acid in inoperable hepatocellular carcinoma: a phase II study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25578

7 January 2021

Antitumor effect of the nucleoside analogs 2-chlorodeoxyadenosine and 2',2'-difluorodeoxycytidine on human hepatoma HepG2 cells

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25578

7 January 2021

DNA topoisomerase expression in tumors--a novel target for chemotherapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25578

7 January 2021

Gemcitabine and doxorubicin for the treatment of patients with advanced hepatocellular carcinoma: a phase I-II trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25578

7 January 2021

Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25578

7 January 2021

Complete response of hepatocellular carcinoma with systemic combination chemotherapy: not to get out the chemotherapy?

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25578

7 January 2021

Pegylated liposomal doxorubicin-based combination chemotherapy as salvage treatment in patients with advanced hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25578

7 January 2021

New utility of an old marker: serial alpha-fetoprotein measurement in predicting radiologic response and survival of patients with hepatocellular carcinoma undergoing systemic chemotherapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25578

7 January 2021

Hormonal treatment of hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25578

7 January 2021

A randomized phase III study of doxorubicin versus cisplatin/interferon alpha-2b/doxorubicin/fluorouracil (PIAF) combination chemotherapy for unresectable hepatocellular carcinoma.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25578

7 January 2021

Gemcitabine plus oxaliplatin (GEMOX) in patients with advanced hepatocellular carcinoma (HCC): results of a phase II study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25578

7 January 2021

Gemcitabine plus oxaliplatin (GEMOX) combined with cetuximab in patients with progressive advanced stage hepatocellular carcinoma: results of a multicenter phase 2 study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25578

7 January 2021

Phase II trial of the combination of bevacizumab and erlotinib in patients who have advanced hepatocellular carcinoma.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25578

7 January 2021

Phase II study of gemcitabine and oxaliplatin in combination with bevacizumab in patients with advanced hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25578

7 January 2021

Identifiers

DOI

10.1002/CNCR.25578

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21058409%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

1 reference